The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
TTLC 2026 | Expanding cohort annotation to validate lung cancer mutation patterns
Mark Jeng, MD, Memorial Sloan Kettering (MSK) Cancer Center, New York, NY, discusses the importance of annotating more patients with lung cancer to validate subsets of a large cohort and potentially applying the findings to a non-MSK cohort for external validation. Additional multivariable analysis and temporal analyses are needed to understand how mutations are acquired over time in patients with local, early-stage lung cancer versus metastatic disease. This interview took place at International Association for the Study of Lung Cancer (IASLC) 2026 Targeted Therapies of Lung Cancer Meeting (TTLC) in Huntington Beach, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
